Vera Therapeutics, Inc.
33.78USD
-1.5000 (-4.25%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | — | — | — | 24.8M | 221.2M |
| Q1 | — | — | — | — | — | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | 4.0M | — |
| Q4 | — | — | — | — | 16.8M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.35 | -2.25 | -2.75 | -4.66 | -6.33 | -4.64 |
| Q1 | -.710 | -.800 | -.560 | -.810 | -1.69 | — |
| Q2 | -.550 | -.460 | -.620 | -1.20 | -1.52 | — |
| Q3 | -.910 | -.450 | -.850 | -1.26 | -1.64 | — |
| Q4 | -1.22* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.601* |
| -.785* |
| -1.42* |
| -1.58 |
| — |